Gary Rothbard, MD, MS

Microvascular disease was found to be associated with lower limb amputation, a risk increased in a synergistic manner in individuals with comorbid PAD.

Scientific statement by AHA detailing the current understanding of menopause transition and its impact on the risk for postmenopausal cardiovascular disease.

Researchers’ goal was to determine empagliflozin’s impact on the central hemodynamic parameters of patients with heart failure with reduced ejection fraction.

Lipid-lowering pharmacotherapy targeting LDL-C was found to be safe and effective in reducing CV and cerebrovascular events, with similar efficacy in older and younger patients.

A novel tool in which clinical risk factors and coronary artery calcium score are added to standard pre-test probability modeling was found to improve risk prediction in suspected obstructive coronary artery disease.

Repeat catheter ablation was found to be safe and to have efficacy comparable with index ablation in alleviating symptoms in patients with atrial fibrillation.

Treatment with vericiguat was not found to improve physical limitation in patients with HFpEF and recent decompensation.

Canagliflozin was found to lower NT-proBNP concentrations in patients with type 2 diabetes who are at risk for cardiovascular disease.

Patients with obstructive coronary artery disease or coronary spasm who suffered a nonfatal cardiac arrest outside the hospital setting and subsequently had a normal electrophysiologic study were found to have excellent prognosis.

Dose de-escalation of prasugrel 1 month after percutaneous coronary intervention in patients with acute coronary syndrome was found to lower the risk for adverse clinical outcomes.